Repligen Corp (NASDAQ:RGEN)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.

Recs

0
Player Avatar pchop123 (80.23) Submitted: 11/14/2012 9:20:07 PM : Outperform Start Price: $5.29 RGEN Score: +8.26

In the land of the blind, a one-eyed man is KING

Featured Broker Partners


Advertisement